Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands (original) (raw)

2012, BMC Infectious Diseases

AI-generated Abstract

This research evaluates the sufficiency of a single dose of the meningococcal serogroup C conjugate vaccine for sufficient protective immunity in various age groups, particularly focusing on findings from the Netherlands. An analysis of serum bactericidal antibody (SBA) titres before and after the introduction of the vaccine shows significant variation in immune response across different ages, suggesting that while a single dose may be effective for some age groups, additional doses may be beneficial to ensure continued immunity.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact